Marshall Wace
NVO

Marshall Wace’s Novo Nordisk NVO Stock Holding History

Marshall Wace’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$81.8M Sell
1,707,104
-1,339,507
-44% -$57.6M 0.06% 244
2026
Q1 		$112M Buy
3,046,611
+2,502,064
+459% +$119M 0.11% 149
2025
Q4 		$27.7M Buy
+544,547
New +$27.8M 0.03% 528
2025
Q3 		– Sell
-31,200
Closed -$2.15M – 3245
2025
Q2 		$2.15M Buy
31,200
+6,075
+24% +$413K ﹤0.01% 1520
2025
Q1 		$1.74M Sell
25,125
-1,142,373
-98% -$94.4M ﹤0.01% 1527
2024
Q4 		$100M Buy
1,167,498
+986,195
+544% +$107M 0.12% 151
2024
Q3 		$21.6M Sell
181,303
-510,138
-74% -$68M 0.03% 487
2024
Q2 		$98.7M Buy
691,441
+689,441
+34,472% +$91.4M 0.13% 141
2024
Q1 		$257K Sell
2,000
-231,879
-99% -$27.6M ﹤0.01% 2161
2023
Q4 		$24.2M Buy
+233,879
New +$23.1M 0.04% 420
2023
Q3 		– Sell
-227,832
Closed -$18.4M – 2536
2023
Q2 		$18.4M Buy
227,832
+164,320
+259% +$13.4M 0.04% 509
2023
Q1 		$5.05M Buy
+63,512
New +$4.5M 0.01% 995
2022
Q4 		– Sell
-23,184
Closed -$1.16M – 3267
2022
Q3 		$1.16M Buy
+23,184
New +$1.24M ﹤0.01% 2339
2022
Q2 		– Sell
-7,332
Closed -$407K – 3717
2022
Q1 		$407K Sell
7,332
-1,746
-19% -$89.6K ﹤0.01% 2862
2021
Q4 		$508K Sell
9,078
-17,366
-66% -$941K ﹤0.01% 2788
2021
Q3 		$1.27M Buy
+26,444
New +$1.28M 0.01% 1860
2021
Q1 		– Sell
-33,246
Closed -$1.16M – 2747
2020
Q4 		$1.16M Sell
33,246
-61,236
-65% -$2.12M 0.01% 1153
2020
Q3 		$3.28M Buy
+94,482
New +$3.15M 0.02% 663
2020
Q2 		– Sell
-1,626
Closed -$49K – 1835
2020
Q1 		$49K Buy
+1,626
New +$48.4K ﹤0.01% 1437
2017
Q1 		– Sell
-793,448
Closed -$14.2M – 612
2016
Q4 		$14.2M Buy
793,448
+436,840
+122% +$7.92M 0.09% 253
2016
Q3 		$7.42M Buy
+356,608
New +$8.84M 0.05% 331
2015
Q4 		– Sell
-68,646
Closed -$1.86M – 1078
2015
Q3 		$1.86M Buy
+68,646
New +$1.94M 0.02% 470

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Marshall Wace's NVO Position: Q2 2026 in Review

Marshall Wace reduced its Novo Nordisk (NVO) stake by 44% in Q2 2026, selling an estimated $57.6M and leaving 1,707,104 shares worth $81.8M. The position accounts for 0.06% of the portfolio, ranked #244.

Marshall Wace first reported a position in NVO in Q3 2015 and has held it in 22 quarters since. The position peaked at $112M in Q1 2026. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Marshall Wace held 1,707,104 shares of Novo Nordisk worth $81.8M as of Q2 2026.
  • Marshall Wace sold 1,339,507 Novo Nordisk shares in Q2 2026, an estimated $57.6M.
  • Novo Nordisk made up 0.06% of Marshall Wace's portfolio in Q2 2026, its #244 holding.
  • Marshall Wace first reported a position in Novo Nordisk in Q3 2015 and has held it in 22 quarters since.
  • Marshall Wace's Novo Nordisk position peaked at $112M in Q1 2026.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.